Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the Netherlands, the United States, and China, has announced a strategic partnership with OPKO Health’s subsidiary, ModeX Therapeutics. The collaboration will fully leverage Nona Bio’s Harbor Mice whole human transgenic mouse platform technology for the development of polyspecific antibodies. Financial details of the agreement have not been disclosed.
Leveraging Harbor Mice Platform Technology
The Harbor Mice platform technology, a proprietary asset of Nona Biosciences, is a significant tool in the development of polyspecific antibodies. These antibodies have the potential to target multiple epitopes simultaneously, offering a more comprehensive approach to therapeutic intervention.
Combining Expertise for Innovation
This partnership brings together the expertise of two companies at the forefront of biotechnology. ModeX Therapeutics, with its focus on innovative therapeutics, will work alongside Nona Biosciences to harness the potential of the Harbor Mice platform. The collaboration aims to accelerate the development of novel polyspecific antibodies that could revolutionize treatment options for various diseases.-Fineline Info & Tech
